Travere Therapeutics Analyst Reviews: A Comprehensive Study of 8 Expert Opinions

jueves, 3 de julio de 2025, 9:00 am ET1 min de lectura
TVTX--

Travere Therapeutics has experienced diverse analyst outlooks, with 5 bullish, 2 somewhat bullish, 1 indifferent, and no bearish ratings in the last 3 months. The average 12-month price target is $33.62, with a high estimate of $47.00 and a low estimate of $23.00. Analysts have raised or lowered their ratings and price targets in response to recent developments.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios